But evidence on the effects of adding tirzepatide to standard care is more limited, resulting in uncertainty for both regulators and clinicians. To address this, researchers analysed clinical practice data from two US health insurance claims databases between May 2022 and May 2025. For individual MACE components, tirzepatide was associated with a 33% lower risk of heart attack compared with sitagliptin, whereas ischaemic stroke showed no meaningful difference. Infections requiring hospital admission were also lower with tirzepatide (one admission prevented for every 48 patients), as was infection related death (one death prevented for every 200 patients) and death from any cause (one death prevented for every 122 patients). Reference:Dani S S, Jayakumar A, Ganatra S. Tirzepatide and cardiovascular outcomes BMJ 2026; 394 :e100366 doi:10.1136/bmj-2026-100366